Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: Comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen

Carcinogenesis

Volumn 17, Issue 9, 1996, Pages 1785-1790

  Pathak, Deena N ^a   Pongracz, Krisztina ^a   Bodell, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIPHENYL 1 (4 HYDROXYPHENYL) BUT 1 ENE; 4 HYDROXYTAMOXIFEN; DNA; PEROXIDASE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DRUG ACTIVATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; UTERUS;

EID: 0029815539     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.9.1785     Document Type: Article

References (59)

1. Fisher, B., Costantino, J., Redmond, C. et al. (1989) A randomized clinical; trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors. N. Engl. J. Med., 320, 479-484.
2. Jaiyesimi, I.A., Buzdar, A.U., Decker, D.A. and Hortobagyi, G.N. (1995) Use of tamoxifen for breast cancer: Twenty-eight years later. J. Clin. Oncol., 13, 513-529.
3. Nayfield, S.G., Karp, J.E., Ford, L.G., Dorr, F.A. and Kramer, B.S. (1991) Potential role of tamoxifen in prevention of breast cancer. J. Natl Cancer Inst., 83, 1450-1459.
4. Andersson, M., Storm, H.H. and Mouridsen, H.T. (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J. Natl Cancer. Inst., 83, 1013-1017.
5. Fischer, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L. and Cronin, W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst., 86, 527-537.
6. van Leeuwen, F.E., Benraadt, J., Coebergh, J.W.W. et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343, 448-452.
7. Rutqvist, L.E., Johansson, H., Signomklao, T., Johansson, U., Fornader, T. and Wuilking, N. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl Cancer. Inst., 87, 645-650.
8. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
9. Hard, G.C., Iatropoulos, M.J., Jordan, K., Radi, L., Kaltenberg, O.P., Imondi, A.R. and Williams, G.M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541.
10. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
11. Vancutsem, P.M., Lazarus, P. and Williams, G.M. (1994) Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54, 3864-3867.
12. Han, X. and Liehr, J.G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363.
13. White, N.H.I., Matteis, F.D., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and its analogues in female Fisher F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
14. Randerath, K., Bi, J., Mabon, N., Sriram, P. and Moorthy, B. (1994) Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis, 15, 797-800.
15. King, C.M. (1995) Tamoxifen and the induction of cancer. Carcinogenesis, 16, 1449-1454.
16. 32P-Postlabeled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis, 16, 1651-1654.
17. Pathak, D., Levay, G. and Bodell, W.J. (1995) DNA adduct formation in the bone marrow of B6C3F1 mice treated with benzene. Carcinogenesis, 16, 1803-1808.
18. Kadlubar, F.F., Miller, J.A. and Miller, E.A. (1977) Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res., 37, 805-814.
19. Kadlubar, F.F., Dooley, K.K., Teitel, C.H. et al. (1991) Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res., 51, 4371-4377.
20. Borgna, J.-L. and Rochefort, H. (1981) Hydroxylated metabolites of tamoxifen are formed in vivo and bound to the estrogen receptor in target tissue. J. Biol. Chem., 256, 859-868.
21. Robertson, D.W., Katzenellenbogen, J.A., Long, D.J., Rorke, E.A. and Katzenellenbogen, B.S. (1982) Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J. Steroid. Biochem., 16, 1-13.
22. Lyman, S.D. and Jordan, V.C. (1985) Metabolism of tamoxifen and its uterotrophic activity. Biochem. Pharmacol., 43, 2787-2794.
23. Robinson, S.P., Langan-Fahey, S.M., Johnson, D.A. and Jordan, V.C. (1991) Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug. Metab. Dispos., 19, 36-43.
24. Lien, E.A., Solheim, E. and Ueland, P.M. (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Res., 51, 4837-4844.
25. Lucas, F.V., Neufield, H.A., Utterback, J.G., Martin, A.P. and Stotz, E. (1955) The effect of estrogen on the production of a peroxidase in the rat uterus. J. Biol. Chem., 214, 775-780.
26. Lyttle, C.R. and DeSombre, E.R. (1977) Uterine peroxidase as a marker for estrogen action. Proc. Natl Acad. Sci.USA, 74, 3162-3166.
27. Holinka, C.F. and Gurpide, E. (1980) Peroxidase activity in glands and stroma of human endometrium. Am. J. Obstet. Gynecol., 1, 599-603.
28. Metzler, M. and McLachlan, J.A. (1978) Peroxidase-mediated oxidation, a posssible pathway for metabolic activation of diethylstilbestrol. Biochem. Biophys. Res. Commun., 85, 874-884.
29. Dwivedy, I., Devanesan, P., Cremonesi, P., Rogan, E. and Cavalieri, E. (1992) Synthesis and characterization of estrogen 2,3 and 3,4 quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase activated catechol estrogens. Chem. Res. Toxicol., 5, 828-833.
30. Davies, A.M., Martin, E.A., Jones, R.M., Lim, C.K., Smith, L.L. and White, I.N.H. (1995) Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis, 16, 539-545.
31. Atkinson, A. and Roy, D. (1995) In vitro conversion of environmental estrogenic chemical bisphenol A to DNA binding metabolites. Biochem. Biophys. Res. Commun., 210, 424-433.
32. Levay, G., Ross, D. and Bodell, W.J. (1992) Peroxidase activation of hydroquinone results in the formation of DNA adducts in HL-60 cells, mouse bone marrow macrophages and human bone marrow. Carcinogenesis, 14, 2329-2334.
33. Pathak, D.N., Pongracz, K. and Bodell, W.J. (1995) Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: Comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis, 16, 11-15.
34. Pongracz, K., Pathak, D.N., Nakamura, T., Burlingame, A.L. and Bodell, W.J. (1995) Activation of the tamoxifen derivative metabolite E to form DNA adducts: Comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res., 55, 3012-3015.
35. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) Protein measurement with folin phenol reagent. J. Biol. Chem., 193, 263-275.
36. Pathak, D.N. and Bodell, W.J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis, 15, 529-532.
37. White, I.N.H., Davies, A., Smith, L.L., Dawson, S. and deMatteis, F. (1993) Induction of CYP2B1 and 3A1 and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol., 45, 21-30.
38. Nuwaysir, E.F., Dragan, Y.P., Jefcoate, C.R., Jordan, V.C. and Pitot, H.C. (1995) Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res., 55, 1780-1786.
39. Ahotupa, M., Hirsimaki, P., Parssinen, R. and Mantyla, E. (1994) Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis, 15, 863-868.
40. 32P-postlabeling and use of metabolic inhibitors for two distict pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094.
41. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J. and Poon, G.K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54, 5518-5522.
42. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J., Hardcastle, I.R., Poon, G.K., Keogh, A. and Strain, A.J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis, 17, 89-94.
43. Gladek, A. and Liehr, J.G. (1989) Mechanism of genotoxicity of diethylstilbestrol in vivo. J. Biol. Chem., 264, 16847-16852.
44. Dragan, Y.P., Fahey, S., Street, K., Vaughan, J., Jordan, V.C. and Pitot, H.C. (1994) Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer 344 rats. Breast Cancer Res. Treat., 31, 11-25.
45. 32P-postlabeling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumor formation. Carcinogenesis, 16, 1299-1304.
46. Senler, T.I., Hofmann, G.E., Sanfilippo, J.S., Barrows, G.H., Dean, W.L. and Wittliff, J.L. (1985) Cytochrome P-450 activity in human leiomyoma and normal myometrium. Am. J. Obstet. Gynecol., 5, 551-555.
47. Liehr, J.G., Ricci, M.J., Jefcoate, C.R., Hannigan, E.V., Hokanson, J.A. and Zhu, B.T. (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis. Proc. Natl Acad. Sci. USA, 92, 9220-9224.
48. AA as a catalyst of hydroxylation induced by TCDD and βNF. Cancer Res., 54, 3140-3144.
49. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol., 49, 1035-1042.
50. Cerutti, P.A. (1985) Prooxidant states and tumor promotion. Science, 227, 375-381.
51. Wang, M.-Y. and Liehr, J.G. (1994) Identification of fatty acid hydroperoxide cofactors in the cytochrome P450 mediated oxidation of estrogens to quinone metabolites: Role and balance of lipid peroxides during estrogen-induced Carcinogenesis. J. Biol. Chem., 269, 284-291.
52. Frenkel, K., Wei, L. and Wei, H (1995) 7,12-Dimethylbenz[a]anthracene induces oxidative DNA modification in vivo. Free. Rad. Biol. Med., 19, 373-380.
53. Levay, G. and Bodell, W.J. (1996) Role of hydrogen peroxide in the formation of DNA adducts in HL-60 cells treated with benzene metabolites. Biochem. Biophys. Res. Commun., 222, 44-49.
54. Hollenberg, P.F. (1992) Mechanisms of cytochrome P450 and peroxidase-catalyzed xenobiotic metabolism. FASEB J., 6, 686-694.
55. Kalyanaraman, B., Sealy, R.C. and Sivarajah, K. (1984) An electron spin resonance study of the o-semiquinones formed during the enzymatic and autoxidation of catechol estrogens. J. Biol. Chem., 259, 14018-14022.
56. Ross, D., Mehlorn, R.J., Moldeus, P. and Smith, M.T. (1985) Metabolism of diethylstilbestrol by horseradish peroxidase and prostaglandin-H-synthase. J.Biol. Chem., 260, 16210-16214.
57. Sipe, H.J., Jordan, S.J., Hanna, P.M. and Mason, R.P. (1994) The metabolism of 17β-estradiol by lactoperoxidase: a possible source of oxidative stress in breast cancer. Carcinogenesis, 15, 2637-2643.
58. Liehr, J.G., DaGue, B.B., Ballatore, A.M. and Henkin, J. (1983) Diethylstilbestrol (DES) quinone: A reactive intermediate in DES metabolism. Biochem. Pharmacol., 32, 3711-3718.
59. Moorthy, B., Sriram, P., Pathak, D.N., Bodell, W.J. and Randerath, K. (1996) Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res., 56, 53-57.